



PTO/8B/08A (10-88)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Section of Information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/040,281
				Filing Date	11/07/2001
				First Named Inventor	Browning, Jeffrey
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	1	of	8	Attorney Docket Number	B129USCP2DV2CO

[illegible]

duplicate  
SB/p3a/b  
7/8/05

[illegible]


Duplicate  
7/8/05

Examiner Signature	Date Considered	8/31/05
-----------------------	--------------------	---------

\*EXAMINER: Indicate if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Unique citation designation number. 2 See attached Kind of U.S. Patent Document. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document and/or WIPO Standard ST. 16 if possible. 6 Ascertain to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioners for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box →



Approved for use through 10/1/98, S.M.B. 0851-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/040,281
		Filing Date	11/07/2001
		First Named Inventor	Browning, Jeffrey
		Group Art Unit	TBD
		Examiner Name	TBD
Sheet	2	of	8
		Attorney Docket Number	B129USCP2DV2CO


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
M	C1	Y. Abe et al., "Expression of Membrane-Associated Lymphotoxin/Tumor Necrosis Factor-Beta on Human Lymphokine Killer Cells", Jpn. J. Canc. Res., 82, pp. 23-26, (1991).	
	C2	Y. Abe et al., "Studies of Membrane-Associated and Soluble (Secreted) Lymphotoxin in Human Lymphokine-Activated T-Killer Cells in Vitro", Lymphokine and Cytokine Research, Vol. 11, pp. 115-121, (1992).	
	C3	Abernold et al., "Internal Amino Acid Sequence Analysis of Proteins Separated by One- or Two-Dimensional Gel Electrophoresis After in situ Protease Digestion on Nitrocellulose", PNAS, Vol. 84, pp. 6970-6974, (1987).	
	C4	B. Aggarwal et al., "Primary Structure of Human Lymphotoxin Derived from 1788 Lymphoblastoid Cell Lines", J. Biol. Chem., Vol. 260, No. 4, pp. 2334-2344, (1985).	
	C5	M. Akashi et al., "Lymphotoxin: Stimulation and Regulation of Colony-Stimulating Factors in Fibroblasts", Blood, 74, No. 7, pp. 2383-2390, (1989).	
	C6	W.F. Anderson, "Human Gene Therapy", Science, Vol. 256, pp. 808-813 (1992).	
	C7	U. Anderson et al., "Characterization of Individual Tumor Necrosis Factor alpha- and beta-Producing Cells after Polyclonal T Cell Activation", J. of Immun. Meth., 123, pp. 239-240, (1989).	
	C8	J.S. Andrews et al., "Characterization of the Receptor for Tumor Necrosis Factor (TNF) and Lymphotoxin (LT) on Human T Lymphocytes", J. Immun., Vol. 144, No. 7, pp. 2528-2591, (1990).	
	C9	Androlewicz et al., "Lymphotoxin is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma", Journal of Biological Chemistry, 267, No. 4, pp. 2547-2547, (1992).	
	C10	R. Armitage et al., "Molecular and Biological Characterization of a Murine Ligand for CD40", Nature, Vol. 357, pp. 80-82, (1992).	
	C11	K. Badier et al., "TNF-alpha Gene Polymorphisms in Type 1 (Insulin-Dependent) Diabetes Mellitus", Diabetologia, 32, 443-448, (1989).	

Examiner Signature	Date Considered	8/31/05
--------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



16:13 FAX 6177424214

LAHIVE&amp;COCKFIELD

015/031

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/089 (10-95)

Approved for use through 10/3/99, OMB 0831-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		<b>Complete If Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/040,281		
		Filing Date	11/07/2001		
		First Named Inventor	Browning, Jeffrey		
		Group Art Unit	TBD		
		Examiner Name	TBD		
Sheet	3	of	8	Attorney Docket Number	B129USCP2DV2CO

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T‡
M	C12	B. Beutler et al., "The History, Properties, and Biological Effects of Cachectin", Biochemistry, Vol. 27, No. 20, pp. 7575-7582, (1988).	
	C13	T. Bringman et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor alpha and beta: Application for Affinity Purification, Immunoassays, and as Structural Probes", Hybridoma, 6, No. 5, pp. 489-507, (1987).	
	C14	J. Browning et al., "Studies on the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines", J. Immun., Vol. 143, No. 6, pp. 1859-1867, (1989).	
	C15	J. Browning et al., "Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma", J. Immunol., Vol. 47, No. 4, pp. 1230-1237, (1991).	
	C16	D. Cavender et al., "Endothelial Cell Activation Induced by Tumor Necrosis Factor and Lymphotoxin", Amer. J. Path., Vol. 134, No. 3, pp. 551-560, (1989).	
	C17	R. Cotran et al., "Endothelial Activation, its Role in Inflammatory and Immune Reactions", Endothelial Cell Biology, pp. 335-347 (1988).	
	C18	N. Damle et al., "Distinct Regulatory Effects of IL-4 and TNF-alpha during CD3-Dependent and CD3-Independent Initiation of Human T-Cell Activation", Lymph Res., Vol. 8, No. 2, pp. 85-97, (1989).	
	C19	M. Eck et al., "The Structure of Tumor Necrosis Factor-alpha at 2.6A Resolution, Implications for Receptor Binding", J. Biological Chemistry, Vol. 264, No. 29, pp. 17595-17605 (1989).	
	C20	M. Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-beta) at 1.9-A Resolution", J. Biological Chemistry, Vol. 267, No. 4, pp. 2119-2122, (1992).	
	C21	T. Parth et al., "Emerging Cytokine Family", Nature, Vol. 358, p. 26, (1992).	
M	C22	G. Fuh et al., "Rational Design of Potent Antagonists to the Human Growth Hormone Receptor", Science, Vol. 256, pp. 1677-1680, (1992).	

DUPLICATE 58/08/03 7/08/01

Examiner Signature	Date Considered
	8/31/05

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐
 PTO/88/088 (10-88)  
 Approved for use through 10/31/89. OMB 0551-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/040,281	
			Filing Date	11/07/2001	
			First Named Inventor	Browning, Jeffrey	
			Group Art Unit	TBD	
			Examiner Name	TBD	
Sheet	4	of	8	Attorney Docket Number	B129USCP2DV2CO


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T
M	C23	D. Goeddel et al., "Tumor Necrosis Factors: Gene Structure and Biological Activities", Cold Spring Harbor Symposia on Quant. Biol., pp. 597-609, (1986).	
	C24	G.A. Granger et al., "Lymphocyte In Vitro Cytotoxicity: Mechanisms of Immune and Non-Immune Small Lymphocyte Mediated Target L Cell Destruction", Journ. of Immun., 101, No. 1, pp. 111-120, (1968).	
	C25	P. Gray, "Molecular Characterization of Human Lymphotoxin", Lymphokines, Vol. 13, pp. 199-208, (1987).	
	C26	P. Gray et al., "Cloning and Expression of cDNA for Human Lymphotoxin, A Lymphokine with Tumor Necrosis Activity", Nature, 312, pp. 721-724, (1984).	
	C27	L. Green et al., "Cytotoxic Lymphokines Produced by Cloned Human Cytotoxic T Lymphocytes", J. of Immun., 135, No. 6, pp. 4034-4043, (1985).	
	C28	L. Green et al., "Rapid Colorimetric Assay for Cell Viability: Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines", J. of Immun. Meth., 70, pp. 257-268, (1984).	
	C29	J. Hiscrodt et al., "Identification of Membrane-Associated Lymphotoxin (LT) on Mitogen-Activated Human Lymphocytes Using Heterologous Anti-LT Antisera in Vitro", Cell. Immun., 34, pp. 326-339, (1977).	
	C30	N. Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen FAS can Mediate Apoptosis", Cell, Vol. 66, pp. 235-243, (1991).	
	C31	E. Jones et al., "Structure of Tumor Necrosis Factor", Nature, 338, pp. 225-228, (1989).	
	C32	A. Kasid et al., "Human Gene Transfer: Characterization of Human Tumor-Infiltrating Lymphocytes as Vehicles for Retrovirus-Mediated Gene Transfer in Man", Proc. Natl. Acad. Sci. USA, 87, pp. 473-477, (1990).	
	C33	M. Kinkhabwala et al., "A Novel Addition to the T Cell Repertory", J. Exp. Med., Vol. 171, pp. 941-946, (1990).	

Examiner Signature	Date Considered
	8/31/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 602. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



18:14 FAX 6177424214

LAHIVE&amp;COCKFIELD

017/031

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/99, OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/040,281
		Filing Date	11/07/2001
		First Named Inventor	Browning, Jeffrey
		Group Art Unit	TBD
		Examiner Name	TBD
Sheet	5	of	8
		Attorney Docket Number	B129USCP2DV2CO

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
M	C34	M. Kriegler et al., "A Novel Form of TNF/Cachectin is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF", Cell, Vol. 53 pp. 45-53, (1988).	
	C35	Liang et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin", Biochem. Biophys. Res. Comm., Vol. 137, No. 2, pp. 847-854, (1986).	
	C36	C. Liu et al., "Identification, Isolation, and Characterization of a Novel Cytotoxin in Murine Cytolytic Lymphocytes", Cell, Vol. 51, pp. 393-403, (1987).	
	C37	C. Liu et al., "Identification and Characterization of a Membrane-Bound Cytotoxin of Murine Cytolytic Lymphocytes that is Related to Tumor Necrosis Factor/Cachectin", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3286-3290, (1989).	
	C38	B. Luentig et al., "Evidence for the Existence of Two Forms of Membrane Tumor Necrosis Factor: An Integral Protein and a Molecule Attached to its Receptor", J. Immun., 143, pp. 4034-4038, (1989).	
	C39	S. Mallett et al., "A New Superfamily of Cell Surface Proteins Related to the Nerve Growth Factor Receptor", Immunology Today, Vol. 12, No. 7, pp. 220-223, (1991).	
	C40	L.J. Old, "Tumor Necrosis Factor (TNF)", Science, Vol. 230, pp. 630-632, (1985).	
	C41	N. Paul et al., "Lymphotoxin", Ann. Rev. Immunol., 6, pp. 407-438, (1988).	
	C42	N. Paul et al., "Lymphotoxin Activation by Human T-Cell Leukemia Virus Type I-Infected Cell Lines: Role NF-kB", J. Virol., Vol. 64, No. 11, pp. 5412-5419, (1990).	
	C43	D. Pennica et al., "Human Tumor Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin", Nature, Vol. 312, pp. 724-729, (1984).	
M	C44	A. Peterson et al., "Monoclonal Antibody and Ligand Binding Sites of the T Cell Erythrocyte Receptor (CD2)", Nature, Vol. 329, pp. 842-846, (1987).	

DUPLICATE 5868-16 7/1/05

Examiner Signature	Date Considered
	8/31/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



18:14 FAX 6177424214

LAHIVE&amp;COCKFIELD

018/031

Please type a plus sign (+) inside this box → ☐PTO/BB/08B (10-86)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete If Known</b>		
			Application Number	10/040,281	
Sheet	6	of	8	Filing Date	11/07/2001
				First Named Inventor	Browning, Jeffrey
				Group Art Unit	TBD
				Examiner Name	TBD
				Attorney Docket Number	B129USCP2DV2CO


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7 <sup>2</sup>
M	C45	P. Pociot et al., "A Tumor Necrosis Factor beta Gene Polymorphism in Relation to Monokine Secretion and Insulin-Dependent Diabetes Mellitus", Scand. J. Immunol., 33, pp. 37-49, (1991).	
	C46	G. Ranges et al., "Tumor Necrosis Factor-alpha as a Proliferative Signal for an IL-2 Dependent T Cell Line: Strict Species Specificity of Action", J. of Immun., Vol. 142, pp. 1203-1208, (1989).	
	C47	G. Ranges et al., "Tumor Necrosis Factor alpha/Cachectin is a Growth Factor for Thymocytes", J. Exp. Med., Vol. 167, pp. 1472-1478, (1988).	
	C48	O.D. Roodman et al., "Tumor Necrosis Factor-alpha and Hematopoietic Progenitors: Effects of Tumor Necrosis Factor on the Growth of Erythroid Progenitors CFU-E and BFU-E and Hematopoietic Cell Lines K562, HL60, and HBL Cells", Exp. Hematology, 15, pp. 928-935, (1987).	
	C49	S. Rosenberg et al., "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma: A Preliminary Report", New Eng. Jour. of Med., Vol. 319, pp. 1676-1680, (1988).	
	C50	N. Ruddle, "Lymphotoxin Redux", Immun. Today, 6, pp. 156-159, (1985).	
	C51	N. Ruddle et al., "Cytotoxicity Mediated by Soluble Antigen and Lymphocytes in Delayed Hypersensitivity", J. Exp. Med., 128, pp. 1237-1279, (1968).	
	C52	N. Ruddle et al., "The Role of Lymphotoxin in Inflammation", Prog. Allergy, Vol. 40, pp. 162-182, (1988).	
	C53	K. Sastry et al., "HIV-1 tat Gene Induces Tumor Necrosis Factor-beta (Lymphotoxin) in a Human beta-Lymphoblastoid Cell Line", J. Biol. Chem., Vol. 265, No. 3, pp. 20091-20093, (1990).	
	C54	T. Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", Cell, Vol. 61, pp. 361-370, (1990).	
M	C55	P. Scheurich et al., "Immunoregulatory Activity of Recombinant Human Tumor Necrosis Factor (TNF)-alpha: Induction of TNF Receptors on Human T Cells and TNF-alpha-Mediated Enhancement of T Cell Responses", J. Immun., Vol. 138, pp. 1786-1790 (1987).	

Examiner Signature	Date Considered
	8/31/05

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/58/088 (10-86)  
 Approved for use through 10/31/99. OMB 0681-0031  
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/040,281
		Filing Date	11/07/2001
		First Named Inventor	Browning, Jeffrey
		Group Art Unit	TBD
		Examiner Name	TBD
Sheet	7	of	8
		Attorney Docket Number	B129USCP2DV2CO

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T*
M	C56	M. Shalaby et al., "The Involvement of Human Tumor Necrosis Factors-alpha and -beta in the Mixed Lymphocyte Reaction", J. Immun., Vol. 141, pp. 499-503, (1988).	
	C57	M. Sigel et al., "Production of Antibodies by Inoculation into Lymph Nodes", Meth. in Enz., Vol. 93, pp. 3-12 (1983).	
	C58	C. Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", Science, 248, pp. 1019-1023, (1990).	
	C59	D. Spriggs et al., "Tumor Necrosis Factor Expression in Human Epithelial Tumor Cell Lines", J. Clin. Invest., Vol. 81, pp. 455-460, (1988).	
	C60	J. Tavernier et al., "Conserved Residues of Tumor Necrosis Factor and Lymphotoxin Constitute the Framework of the Trimeric Structure", Fed. Eur. Biochem. Soc. Letters, Vol. 257, No. 2, pp. 315-318, (1989).	
	C61	H. Thomas et al., "Biological Approaches to Cancer Therapy", J. Int. Med. Res., 17, pp. 191-204 (1989).	
	C62	M. Turner et al., "Human T Cells from Autoimmune and Normal Individuals can Produce Tumor Necrosis Factor", Eur. J. Immun., 17, pp. 1807-1814 (1987).	
	C63	E. Tschachler et al., "Human Retrovirology: Constitutive Expression of Lymphotoxin (Tumor Necrosis Factor beta) in HTLV-I-Infected Cell Lines", Raven Press, pp. 105-113, (1990).	
	C64	R. Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis", Nature, 356, pp. 314-317, (1992).	
	C65	C. Ware et al., "Mechanisms of Lymphocyte-Mediated Cytotoxicity", J. Immun., Vol. 126, pp. 1927-1933, (1981).	
	C66	C. Ware et al., "Human T Cell Hybridomas Producing Cytotoxic Lymphotoxins: Induction of Lymphotoxin Release and Killer Cell Activity by Anti-CD3 Monoclonal Antibody or Lectins and Phorbol Ester", Lymphokine Res., Vol. 5, No. 4, pp. 313-324, (1986).	

Examiner Signature	Date Considered
	8/3/05

\*EXAMINER'S Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Unique citation designation number. \* Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Section of Information unless it contains a valid OMB control number.

Substitution for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	8	of	8
-------	---	----	---

**Complete if Known**

Application Number	10/040,281
Filing Date	11/07/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	B129USCP2DY2CO

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

DUPLICATE ✓  
58692/6 7/8/05

**Examiner  
Signature**

Date Considered


8/31/05

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.





PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/040,281
				Filing Date	November 7, 2001
				First Named Inventor	Jeffrey L. Browning
				Art Unit	1635
				Examiner Name	Sean McGarry
Sheet	1	of	5	Attorney Docket Number	BGN-B129CP2D2CN RCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
JMA	A1	4,338,397	07-06-1982	Gilbert, <i>et al.</i>	
	A2	4,758,549	07-19-1988	Mitsubishi, <i>et al.</i>	
	A3	4,822,605	04-18-1989	Powell	
	A4	4,849,509	07-18-1989	Thurin, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
JMA	B1	EP 0367575	05-09-1990	Sankyo Company		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
JMA	C1	Abe, Y., <i>et al.</i> "Expression of membrane-associated lymphotoxin/tumor necrosis factor-beta on human lymphokine-activated killer cells." <i>Jpn J Cancer Res.</i> 1991 Jan; 82(1):23-6.				
	C2	Abe, Y., <i>et al.</i> "Studies of membrane-associated and soluble (secreted) lymphotoxin in human lymphokine-activated T-killer cells in vitro." <i>Lymphokine Cytokine Res.</i> 1992 Apr; 11(2):115-21.				
	C3	Abersold, <i>et al.</i> "Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose." <i>PNAS.</i> 1987; 84:6970-4.				
	C4	Aggarwal, B.B., <i>et al.</i> "Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line." <i>J Biol Chem.</i> 1985 Feb 25; 260(4):2334-44.				
	C5	Akashi, M., <i>et al.</i> "Lymphotoxin: stimulation and regulation of colony-stimulating factors in fibroblasts." <i>Blood.</i> 1989 Nov 15; 74(7):2383-90.				
	C6	Anderson, W.F. "Human gene therapy." <i>Science.</i> 1992 May 8; 256(5058):808-13.				
	C7	Anderson, U., <i>et al.</i> "Characterization of individual tumor necrosis factor alpha- and beta-producing cells after polyclonal T cell activation." <i>J. of Immun. Meth.</i> 1989; 123:233-40.				
	C8	Andrews, J.S., <i>et al.</i> "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes." <i>J Immunol.</i> 1990 Apr 1; 144(7):2582-91.				
	C9	Androlewicz, M.J., <i>et al.</i> "Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma." <i>J Biol Chem.</i> 1992 Feb 5; 267(4):2542-7.				

Examiner Signature		Date Considered	8/31/05
-----------------------	--	--------------------	---------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/040,281
				Filing Date	November 7, 2001
				First Named Inventor	Jeffrey L. Browning
				Art Unit	1635
				Examiner Name	Sean McGarry
Sheet	2	of	5	Attorney Docket Number	BGN-B129CP2D2CN RCE

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
M	C10	Armitage, R.J., <i>et al.</i> "Molecular and biological characterization of a murine ligand for CD40." <i>Nature</i> . 1992 May 7; 357(6373):80-2.		
	C11	Badenhoop, K., <i>et al.</i> "TNF-alpha gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus." <i>Diabetologia</i> . 1989 Jul; 32(7):445-8.		
	C12	Beutler, B., <i>et al.</i> "The history, properties, and biological effects of cachectin." <i>Biochemistry</i> . 1988 Oct 4; 27(20):7575-82.		
	C13	Bringingman, T.S., <i>et al.</i> "Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes." <i>Hybridoma</i> . 1987 Oct; 6(5):489-507.		
	C14	Browning, J.L., <i>et al.</i> "Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines." <i>J Immunol</i> . 1989 Sep 15; 143(6):1859-67.		
	C15	Browning, J.L., <i>et al.</i> "Lymphotoxin and an associated 33-kDa glycoprotein are expressed on the surface of an activated human T cell hybridoma." <i>J Immunol</i> . 1991 Aug 15; 147(4):1230-7.		
	C16	Cavender, D.E., <i>et al.</i> "Endothelial cell activation induced by tumor necrosis factor and lymphotoxin." <i>Am J Pathol</i> . 1989 Mar; 134(3):551-60.		
	C17	Cotran, R.S., <i>et al.</i> "Endothelial activation, its role in inflammatory and immune reactions." <i>Endothelial Cell Biology</i> . 1988; 335-47.		
	C18	Damle, N.K., <i>et al.</i> "Distinct regulatory effects of IL-4 and TNF-alpha during CD3-dependent and CD3-independent initiation of human T-cell activation." <i>Lymphokine Res</i> . 1989; 8(2):85-97.		
	C19	Eck, M.J., <i>et al.</i> "The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding." <i>J Biol Chem</i> . 1989 Oct 15; 264(29):17595-605.		
	C20	Eck, M.J., <i>et al.</i> "The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution." <i>J Biol Chem</i> . 1992 Feb 5; 267(4):2119-22.		
	C21	Farrah, T., <i>et al.</i> "Emerging cytokine family." <i>Nature</i> . 1992 Jul 2; 358(6381):26.		
	C22	Fuh, G., <i>et al.</i> "Rational design of potent antagonists to the human growth hormone receptor." <i>Science</i> . 1992 Jun 19; 256(5064):1677-80.		
	C23	Goeddel, D.V., <i>et al.</i> "Tumor necrosis factors: gene structure and biological activities." <i>Cold Spring Harb Symp Quant Biol</i> . 1986; 51:597-609.		
	C24	Granger, G.A., <i>et al.</i> "Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction." <i>J Immunol</i> . 1968 Jul; 101(1):111-20.		
	C25	Gray, P.W. "Molecular characterization of human lymphotoxin." <i>Lymphokines</i> . 1987; 13:199-208.		
	C26	Gray, P.W., <i>et al.</i> "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity." <i>Nature</i> . 1984 Dec 20-1985 Jan 2; 312(5996):721-4.		
	C27	Green, L.M., <i>et al.</i> "Cytotoxic lymphokines produced by cloned human cytotoxic T lymphocytes. I. Cytotoxins produced by antigen-specific and natural killer-like CTL are dissimilar to classical lymphotoxins." <i>J Immunol</i> . 1985 Dec; 135(6):4034-43.		
M	C28	Green, L.M., <i>et al.</i> "Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines." <i>J Immunol Methods</i> . 1984 May 25; 70(2):257-68.		
Examiner Signature			Date Considered	8/31/05



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/040,281
				Filing Date	November 7, 2001
				First Named Inventor	Jeffrey L. Browning
				Art Unit	1635
				Examiner Name	Sean McGarry
Sheet	3	of	5	Attorney Docket Number	BGN-B129CP2D2CN RCÉ

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
M	C29	Hiserodt, J.C., <i>et al.</i> "Identification of membrane-associated lymphotoxin (LT) on mitogen-activated human lymphocytes using heterologous anti-LT antisera in vitro." <i>Cell Immunol.</i> 1977 Dec; 34(2):326-39.		
	C30	Itoh, N., <i>et al.</i> "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis." <i>Cell.</i> 1991 Jul 26; 66(2):233-43.		
	C31	Jones, E.Y., <i>et al.</i> "Structure of tumour necrosis factor." <i>Nature.</i> 1989 Mar 16; 338(6212):225-8.		
	C32	Kasid, A., <i>et al.</i> "Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man." <i>Proc Natl Acad Sci USA.</i> 1990 Jan; 87(1):473-7.		
	C33	Kinkhabwala, M., <i>et al.</i> "A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells." <i>J Exp Med.</i> 1990 Mar 1; 171(3):941-6.		
	C34	Kriegler, M., <i>et al.</i> "A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF." <i>Cell.</i> 1988 Apr 8; 53(1):45-53.		
	C35	Liang, C.M., <i>et al.</i> "Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin." <i>Biochem Biophys Res Commun.</i> 1986 Jun 13; 137(2):847-54.		
	C36	Liu, C.C., <i>et al.</i> "Identification, isolation, and characterization of a novel cytotoxin in murine cytolytic lymphocytes." <i>Cell.</i> 1987 Nov 6; 51(3):393-403.		
	C37	Liu, C.C., <i>et al.</i> "Identification and characterization of a membrane-bound cytotoxin of murine cytolytic lymphocytes that is related to tumor necrosis factor/cachectin." <i>Proc Natl Acad Sci USA.</i> 1989 May; 86(9):3286-90.		
	C38	Luetting, B., <i>et al.</i> "Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor." <i>J Immunol.</i> 1989 Dec 15; 143(12):4034-8.		
	C39	Mallett, S., <i>et al.</i> "A new superfamily of cell surface proteins related to the nerve growth factor receptor." <i>Immunol Today.</i> 1991 Jul; 12(7):220-3.		
	C40	Old, L.J. "Tumor necrosis factor (TNF)." <i>Science.</i> 1985 Nov 8; 230(4726):630-2.		
	C41	Paul, N.L., <i>et al.</i> "Lymphotoxin." <i>Annu Rev Immunol.</i> 1988; 6:407-38.		
	C42	Paul, N.L., <i>et al.</i> "Lymphotoxin activation by human T-cell leukemia virus type I-infected cell lines: role for NF-kappa B." <i>J Virol.</i> 1990 Nov; 64(11):5412-9.		
	C43	Pennica, D., <i>et al.</i> "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin." <i>Nature.</i> 1984 Dec 20-1985 Jan 2; 312(5996):724-9.		
	C44	Peterson, A., <i>et al.</i> "Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2)." <i>Nature.</i> 1987 Oct 29-Nov 4; 329(6142):842-6.		
	C45	Pociot, F., <i>et al.</i> "A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus." <i>Scand J Immunol.</i> 1991 Jan; 33(1):37-49.		
M	C46	Ranges, G.E., <i>et al.</i> "Tumor necrosis factor-alpha as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action." <i>J Immunol.</i> 1989 Feb 15; 142(4):1203-8.		
Examiner Signature			Date Considered	8/31/05



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
				Application Number	10/040,281
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	November 7, 2001
				First Named Inventor	Jeffrey L. Browning
				Art Unit	1635
				Examiner Name	Sean McGarry
				Attorney Docket Number	BGN-B129CP2D2CN RCE
Sheet	4	of	5		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
M	C47	Ranges, G.E., <i>et al.</i> "Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines." <i>J Exp Med.</i> 1988 Apr 1; 167(4):1472-8.		
	C48	Roodman, G.D., <i>et al.</i> "Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells." <i>Exp Hematol.</i> 1987 Oct; 15(9):928-35.		
	C49	Rosenberg, S.A., <i>et al.</i> "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report." <i>N Engl J Med.</i> 1988 Dec 22; 319(25):1676-80.		
	C50	Ruddle, N.H. "Lymphotoxin redux." <i>Immun. Today.</i> 1985; 6:156-9.		
	C51	Ruddle, N.H., <i>et al.</i> "Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon." <i>J Exp Med.</i> 1968 Dec 1; 128(6):1237-54.		
	C52	Ruddle, N.H., <i>et al.</i> "The role of lymphotoxin in inflammation." <i>Prog Allergy.</i> 1988; 40:162-82.		
	C53	Sastry, K.J., <i>et al.</i> "HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line." <i>J Biol Chem.</i> 1990 Nov 25; 265(33):20091-3.		
	C54	Schall, T.J., <i>et al.</i> "Molecular cloning and expression of a receptor for human tumor necrosis factor." <i>Cell.</i> 1990 Apr 20; 61(2):361-70.		
	C55	Scheurich, P., <i>et al.</i> "Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses." <i>J Immunol.</i> 1987 Mar 15; 138(6):1786-90.		
	C56	Shalaby, M.R., <i>et al.</i> "The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction." <i>J Immunol.</i> 1988 Jul 15; 141(2):499-503.		
	C57	Sigel, M.B., <i>et al.</i> "Production of antibodies by inoculation into lymph nodes." <i>Methods Enzymol.</i> 1983; 93:3-12.		
	C58	Smith, C.A., <i>et al.</i> "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins." <i>Science.</i> 1990 May 25; 248(4958):1019-23.		
	C59	Spriggs, D.R., <i>et al.</i> "Tumor necrosis factor expression in human epithelial tumor cell lines." <i>J Clin Invest.</i> 1988 Feb; 81(2):455-60.		
	C60	Tavernier, J., <i>et al.</i> "Conserved residues of tumour necrosis factor and lymphotoxin constitute the framework of the trimeric structure." <i>FEBS Lett.</i> 1989 Nov 6; 257(2):315-8.		
	C61	Thomas, H., <i>et al.</i> "Biological approaches to cancer therapy." <i>J Int Med Res.</i> 1989 May-Jun; 17(3):191-204.		
	C62	Turner, M., <i>et al.</i> "Human T cells from autoimmune and normal individuals can produce tumor necrosis factor." <i>Eur J Immunol.</i> 1987 Dec; 17(12):1807-14.		
	C63	Tschachler, E., <i>et al.</i> "Human retrovirology: constitutive expression of lymphotoxin (tumor necrosis factor beta) in HTLV-I-infected cell lines." Raven Press, 1990; pp. 105-13.		
C64	Watanabe-Fukunaga, R., <i>et al.</i> "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis." <i>Nature.</i> 1992 Mar 26; 356(6367):314-7.			
C65	Ware, C.F., <i>et al.</i> "Mechanisms of lymphocyte-mediated cytotoxicity. II. biochemical and serologic identification of a precursor lymphotoxin form (pre-LT) produced by MLC-sensitized human T lymphocytes in vitro." <i>J Immunol.</i> 1981 May; 126(5):1927-33.			
Examiner Signature			Date Considered	8/31/05

JUL 08 2005



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/040,281
				Filing Date	November 7, 2001
				First Named Inventor	Jeffrey L. Browning
				Art Unit	1635
				Examiner Name	Sean McGarry
Sheet	5	of	5	Attorney Docket Number	BGN-B129CP2D2CN RCE

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
M	C66	Ware, C.F., et al. "Human T cell hybridomas producing cytotoxic lymphokines: induction of lymphotoxin release and killer cell activity by anti-CD3 monoclonal antibody or lectins and phorbol ester." <i>Lymphokine Res.</i> 1986; 5(4):313-24.			
	C67	Ware, C.F., et al. "Regulation of the CTL lytic pathway by tumor necrosis factor." <i>Cellular Immunity and the Immunotherapy of Cancer</i> . UCLA Symposia on Molecular and Cell Biology, M.T. Lotze and O.J. Finn, Eds., 1990; 135:121-8 (Wiley-Liss Inc., New York).			
	C68	Ware, C.F., et al. "Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells." <i>J Immunol.</i> 1992 Dec 15; 149(12):3881-8.			
	C69	Wysocki, L.J., et al. "'Panning" for lymphocytes: a method for cell selection." <i>Proc Natl Acad Sci USA.</i> 1978 Jun; 75(6):2844-8.			
	C70	Yamanaka, H.I., et al. "Identity of human B-cell line cytotoxic lymphokine with tumor necrosis factor type beta." <i>Proc Natl Acad Sci USA.</i> 1989 Feb; 86(4):1343-7.			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	8/31/05
--------------------	--	-----------------	---------